- Home
- MXCT
MXCT
MaxCyte Inc.
as 03-28-2025 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 361.8M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 750.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $5.26 | Next Earning Date: | 03-11-2025 |
| Revenue: | $38,627,000 | Revenue Growth: | -6.45% |
| Revenue Growth (this year): | 20.01% | Revenue Growth (next year): | 26.64% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandoval David I. | MXCT | GENERAL COUNSEL | Mar 18 '25 | Sell | $3.18 | 353 | $1,122.29 | 64,219 | |
| Swirsky Douglas J | MXCT | CHIEF FINANCIAL OFFICER | Mar 18 '25 | Sell | $3.18 | 6,939 | $22,061.16 | 111,811 | |
| Soleymannezhad Ali | MXCT | Chief Commercial Officer | Mar 18 '25 | Sell | $3.18 | 1,211 | $3,850.13 | 59,439 | |
| Johnston John Joseph | MXCT | Director | Jan 27 '25 | Sell | $4.65 | 3,000 | $13,935.00 | 141,950 | |
| Sandoval David I. | MXCT | GENERAL COUNSEL | Jan 13 '25 | Sell | $4.54 | 4,466 | $20,271.62 | 64,219 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
GuruFocus.com
19 days ago
MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
GlobeNewswire
20 days ago
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
MT Newswires
2 months ago
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics
GlobeNewswire
2 months ago
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
GlobeNewswire
2 months ago
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
MT Newswires
2 months ago
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx
GlobeNewswire
2 months ago
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
Simply Wall St.
2 months ago
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.